STAT+: Pharmalittle: Biogen ALS drug trial yields mixed signals; Novartis makes U.S. growth its top priority

Hello, everyone, and how are you today? A dank cloudy cover greeted us this morning, but we are ignoring the gloom by keeping busy. After all, there is much to be done. There are deadlines to meet, a variety of reading material to digest, and calls to make. We trust you can relate. So please join us as we fortify ourselves with more cups of stimulation — we are back to blueberry cobbler — and get started. Hope you conquer the world and accomplish much. And of course, be in touch. …

Over the last six years, a venture capital team run by Bayer invested roughly $1.5 billion into small biotech startups and now the unit is ramping up with plans to invest a nearly identical pot of money — this time, $1.3 billion — in half the time, according to STAT. Bayer launched its venture arm, Leaps…
Click here to view original post

Be the first to comment

Leave a Reply

Your email address will not be published.